Intended for UK Healthcare Professionals only. Adverse Event Reporting information can be found at the bottom of the page.
This website contains promotional information

Velariq® (oxybutynin hydrochloride)

Prescribing Information

VELARIQ® (oxybutynin hydrochloride) is indicated for the suppression of neurogenic detrusor overactivity (NDO) in children from 6 years of age and adults, who are managing bladder emptying by clean intermittent catheterisation, not adequately managed with oral anticholinergics.1

1 ml solution contains 1 mg oxybutynin hydrochloride. One scaled prefilled ready-to-use syringe with 10 ml solution contains 10 mg oxybutynin hydrochloride.1

Dosing & administration1

  • Initial dose adjustment shall be done by a neuro-urologist under close urodynamic control.
  • There are no fixed rules for the dose regimen as high interindividual differences in bladder pressure and doses required to improve neurogenic detrusor overactivity exist. The dose regimen (doses and timings) must therefore be determined individually according to the patient's need.
  • Individual dosages will be applied to control uro-dynamic parameters sufficiently (maximum detrusor pressure < 40 cm H2O) aiming at complete inhibition of neurogenic detrusor overactivity.
  • In the course of intravesical oxybutynin therapy, urodynamic parameters shall be controlled in regular intervals as defined by the attending urologist.1

Paediatric population

  • The safety and efficacy of oxybutynin hydrochloride in children aged 0 to 5 years of age have not yet been established.1

Dose recommendations in the following age groups

  • The dose recommendations have been calculated according to the body weight percentiles of the different age groups.1
Age group Age [years] Recommended daily starting dose [mg] Recommended total daily dose [mg]
Children 6 - 12 2 2 - 30
Adolescents 12 - 18 10 10 - 40
Adults 19 - 65 10 10 - 40
Elderly (from 65 years)* from 65 10 10 - 30

*As with other anticholinergic drugs caution should be observed in frail and elderly patients, especially if doses higher than 30 mg per day are considered as required

For full dosing information please see the SPC

Method of administration for Intravesical use1

  • To ensure safe and effective treatment, patients must be familiar with the procedure of clean intermittent catheterisation (CIC). The patients and/or relative, carer shall be trained on CIC and the administration procedure by specialised health care professionals.
  • As soon as the environmental conditions are aseptic, a sterile disposable urethral catheter is inserted into the bladder. The bladder has to be drained completely before the instillation.
  • The scaled prefilled syringe is taken from the bag and the cap is removed from the syringe.
  • A stepped tapered luer-lock adapter is screwed on the tip of the syringe. With the help of the stepped tapered luer-lock adapter, the syringe is connected to the catheter. The required amount of the oxybutynin solution is instilled into the bladder by constant pressing on the plunger of the syringe.
  • If the application of less than 10 ml (one syringe content) is required, the solution that is not used remains in the syringe and should be taken to a pharmacy for disposal, later.
  • After the instillation the catheter is removed.
  • The instilled solution remains in the bladder until the next catheterisation.
  • Any unused medicinal product, the urethral catheter and the stepped tapered luer-lock adapter have to be discarded.
  • The duration of treatment depends on the symptoms, the underlying disease and / or the treatment goal and is determined by the treating physician.

Safety and Monitoring

Access our full safety and monitoring information or please refer to section 4 of the SPC.

Availability

VELARIQ® is now available to prescribe in the UK. To arrange a visit with your local MEDICE UK Key Account Manager please click below.

Contact MEDICE UK

Contact us

If you would like to find out more about our treatments or therapy area expertise, please contact us


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

Date of Preparation: August 2024 UK-VEL-2024-1644-v1

Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk